Skip to content

Christine A. Sannerud

2 papers in the library · 9 citations · publishing 1996-2009

Papers

Intravenous self-injection of four novel phenethylamines in baboons

Behavioural Pharmacology August 1, 1996 Christine A. Sannerud, B. Kaminski, Roland R. Griffiths 9 citations

Intravenous self-administration of four substituted phenethylamines was evaluated in baboons trained to self-inject cocaine. High doses of MDE and N-OH-MDA maintained self-injection, while NNDMA did not reliably do so, and BDMPEA maintained self-injection in each of three baboons at one or more doses. Intermediate to high doses of all four compounds decreased food pellet intake. In some baboons, high doses of N-OH-MDA, NNDMA, and BDMPEA produced signs of behavioral toxicity similar to those of classic psychomotor stimulants, though severity and profile differed between compounds. The study documents both similarities and differences in the behavioral profiles of these phenethylamines.

Current Drug Scheduling Reviews Reported by DEA

The FASEB Journal April 1, 2009 Sandy Ghozland, Srihari R. Tella, Michelle D. Walker et al.

The DEA collects and reviews scientific, medical, and other data on substances with abuse potential to determine whether they should be placed under the Controlled Substances Act (CSA). Ongoing scheduling processes involve indiplon, carisoprodol, dextromethorphan, salvinorin A, and several petitions regarding nabilone, methylphenidate, marijuana and tetrahydrocannabinols, tramadol, anabolic steroids, and sibutramine. Many hallucinogens, including 5-MeO-DMT, 5-MeO-AMT, 5-MeO-DET, 5-MeO-MIPT, DIPT, 4-OH-DIPT, 2C-I, 2C-T-2, and Bromo-dragonfly, are under review for possible control. Chemical and pharmacological studies for DOC, 2C-C, 2C-D, and 2C-E are ongoing. Additionally, to comply with the 1971 Convention on Psychotropic Substances, DEA is reviewing zipeprol, amineptine, mesocarb, 4-MTA, and brotizolam for control under the CSA.